Royalty Pharma Sub-Manager, LLC reported 4 positions worth $241.92M for the quarter ended Jun 30, 2026, up 40.0% on the prior quarter. It opened 1 new position, added to 0, trimmed 0 and exited 1. Its largest holding is Cytokinetics Inc at 34.5% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| KLRA Kailera Therapeutics, Inc. | +2.46M | – | $54.09M | 22.36% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| BCRX Biocryst Pharmaceuticals Inc | -3.85M | -100.0% | $36.62M | Exited |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| KLRA Kailera Therapeutics, Inc. | +2.46M | $54.09M | 22.36% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| BCRX Biocryst Pharmaceuticals Inc | -3.85M | $36.62M | 21.19% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | CYTK Cytokinetics Inc | Healthcare | 980.4K | $83.52M | 34.52% | 0 | 0.0% | Unchanged | 0.71% |
| 2 | BCAX Bicara Therapeutics Inc. | Healthcare | 2.39M | $60.61M | 25.05% | 0 | 0.0% | Unchanged | 3.52% |
| 3 | KLRA Kailera Therapeutics, Inc. | Healthcare | 2.46M | $54.09M | 22.36% | +2.46M | – | New | 1.89% |
| 4 | BHVN Biohaven Ltd. | Healthcare | 2.94M | $43.70M | 18.06% | 0 | 0.0% | Unchanged | 1.94% |
Tip. Select a row to see that position’s full history at Royalty Pharma Sub-Manager.
As of its Q2 2026 13F filing, Royalty Pharma Sub-Manager, LLC’s five largest positions were Cytokinetics Inc (CYTK) at 34.5%, Bicara Therapeutics Inc. (BCAX) at 25.1%, Kailera Therapeutics, Inc. (KLRA) at 22.4%, Biohaven Ltd. (BHVN) at 18.1% of the reported portfolio.
Royalty Pharma Sub-Manager, LLC reported a 13F portfolio worth $241.92M across 4 positions for Q2 2026. That is up 40.0% from the previous quarter.
Its largest purchases by value were Kailera Therapeutics, Inc. ($54.09M). It opened 1 new positions.
Its largest sales by value were Biocryst Pharmaceuticals Inc ($36.62M). It exited 1 positions entirely.
From the Form 13F-HR reports Royalty Pharma Sub-Manager, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.